Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR ANNOUNCES ADDITIONAL AGREEMENT WITH LEADING BIOPHARMACEUTICAL COMPANY
Cambridge, UK, 5 July 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has entered into an agreement with a leading biopharmaceutical company to support the ongoing development of a biosimilar product.
This revenue-generating collaboration follows an earlier technology partnership between the two companies, utilising Arecor's proprietary technology platform, Arestat™, and formulation expertise.
Sarah Howell, Chief Executive Officer of Arecor, said: "This collaboration demonstrates the strength of our know-how and expertise and the value that expertise can bring to our partners' research programmes. We're delighted to be working again with an existing partner, strengthening a key relationship and building on our track record of partnerships with leading biopharmaceutical and biotechnology companies."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977 Email: [email protected] |
|
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
|
Consilium Strategic Communications |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com